Website
www.gsk.hu
Logo
Background and history of the corporation or institution
GlaxoSmithKline Biologicals Kft. in Gödöllő is one of the world’s center of excellence for vaccine manufacturing. The company in Hungary has been producing vaccine components, bulk antigen and carrier protein for Diphtheria and Tetanus since 2002, building on a 50-year scientific competence heritage in Budapest. From here we are providing a safe work environment to more than 340 persons while operating in full compliance with Hungarian and International requirements with the aim to protect the health of employees and patients worldwide. Gödöllő plays a critical role in the supply of vaccines as a strategic provider for GSK of protein carrier used in GSK’s pneumococcal vaccine Synflorix and in combo vaccines of GSK’s Infanrix and Boostrix portfolio.
So far, GSK invested around 170 million Euros in Gödöllő to guarantee the state-of-the-art capabilities either in infrastructure, technologies, automation, and human competencies to create a highly proficient environment for the manufacturing, development and testing of biologicals products.
Here at our site, engineers, scientists and highly skilled technicians are all contributing to global health to get ahead of disease, working every day in an international and dynamic environment, fully leveraging everyone’s talent and enabling each individual to keep learning and growing so that anyone can thrive. We are proud to have a diverse workforce of different nationalities presented and cooperating and collaborating together with a gender balance and with a unique factor of employing nearly half of our employees with a university degree.
GSK is also committed to the wealth of local communities, including protecting the environment where the company is operating and, for this, we are actively engaged into reducing our carbon footprint, the consumption of water and of any other natural resource. The Gödöllő plant is fully aligned with these principles, leading the way in vaccines responsible manufacturing. Early 2022 a thorough site-wise project was launched with the aim at reaching total CO2 carbon neutrality for the site by 2030, for a better and brighter future for nature and future generations.
At GSK we unite science, technology and talent to get ahead of disease together. We prevent and treat disease with vaccines, specialty, and general medicines. We are one of the world’s largest vaccines companies, with the broadest portfolio of vaccines on the market and a strong pipeline of vaccines in development. We supply more than 20 vaccines to more than 160 countries to help protect people from a range of diseases throughout their lives. For further information, please visit www.gsk.com
So far, GSK invested around 170 million Euros in Gödöllő to guarantee the state-of-the-art capabilities either in infrastructure, technologies, automation, and human competencies to create a highly proficient environment for the manufacturing, development and testing of biologicals products.
Here at our site, engineers, scientists and highly skilled technicians are all contributing to global health to get ahead of disease, working every day in an international and dynamic environment, fully leveraging everyone’s talent and enabling each individual to keep learning and growing so that anyone can thrive. We are proud to have a diverse workforce of different nationalities presented and cooperating and collaborating together with a gender balance and with a unique factor of employing nearly half of our employees with a university degree.
GSK is also committed to the wealth of local communities, including protecting the environment where the company is operating and, for this, we are actively engaged into reducing our carbon footprint, the consumption of water and of any other natural resource. The Gödöllő plant is fully aligned with these principles, leading the way in vaccines responsible manufacturing. Early 2022 a thorough site-wise project was launched with the aim at reaching total CO2 carbon neutrality for the site by 2030, for a better and brighter future for nature and future generations.
At GSK we unite science, technology and talent to get ahead of disease together. We prevent and treat disease with vaccines, specialty, and general medicines. We are one of the world’s largest vaccines companies, with the broadest portfolio of vaccines on the market and a strong pipeline of vaccines in development. We supply more than 20 vaccines to more than 160 countries to help protect people from a range of diseases throughout their lives. For further information, please visit www.gsk.com